MIBG in Aging and Neurologic Disorders

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT05514106
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Dementia
  • Lewy Body Disease
  • Mild Cognitive Impairment
  • Parkinsonism
  • REM Sleep Behavior Disorder

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

  • meta-iodobenzylguanidine (MIBG) (123I) — DRUG
    1 administration of 123I-MIBG for a single SPECT scan
  • 123I-MIBG scintigraphy — DIAGNOSTIC_TEST
    SPECT scan involving 123I-MIBG as the ligand

Study Details

The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.

Key Dates

Start date
May 8, 2023
Status verified
Jul 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Myocardial 123I-MIBG scintigraphy imaging
    Subjects with with normal neurologic functioning, REM sleep without atonia, RBD, parkinsonism, cognitive impairment, or some combination of these will undergo myocardial 123I-MIBG scintigraphy imaging

Primary Outcome Measure

Correlate myocardial 123I-MIBG scintigraphy findings [ Time Frame: 10 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies